Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer

Clinical Cancer Research

Volumn 5, Issue 6, 1999, Pages 1523-1537

  Coukos, George ^a   Makrigiannakis, Antonis ^a   Kang, Eugene H ^a   Caparelli, David ^a   Benjamin, Ivor ^a   Kaiser, Larry R ^a   Rubin, Stephen C ^a   Albelda, Steven M ^a   Molnar Kimber, Katherine L ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; FEMALE; GENE THERAPY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; VIRUS REPLICATION;

ANIMALS; CELL ADHESION; CELL SURVIVAL; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; HERPES SIMPLEX; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SIMPLEXVIRUS; SURVIVAL RATE; TERATOCARCINOMA; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0033018401     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Ries, L. Survival and treatment differences by age. Cancer (Phila.), 71: 524-529, 1993.
2. Benjamin, I., and Rubin, S. C. Modern treatment options in epithelial ovarian carcinoma. Curr. Opin. Obstet. Gynecol., 10: 29-32, 1998.
3. Coukos, G., and Rubin, S. Chemotherapy resistance in ovarian cancer; new molecular perspectives. Obstet. Gynecol., 9: 783-792, 1998.
4. DiSaia, P. J., and Creasman, W. T. Epithelial ovarian cancer. In: Clinical Gynecologic Oncology. St. Louis, MO; Mosby-Year Book, Inc., 1993.
5. Tong, X., Block, A., Chen, S., Contant, C., Agoulnik, I., Blankenburg, K., Kaufman, R., Woo, S., and Kieback, D. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol. Oncol., 61: 175-179, 1996.
6. Behbakht, K., Benjamin, I., Chiu, H., Eck, S., Van Deerlin, P., Rubin, S., and Boyd, J. Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. Am. J. Obstet. Gynecol., 175: 1260-1265, 1996.
7. Deshane, J., Siegal, G. P., Alvarez, R. D., Wang, M. H., Feng, M., Cabrera, G., Liu, T., Kay, M., and Curiel, D. T. Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest., 96: 2980-2989, 1995.
8. Mujoo, K., Maneval, D., Anderson, S., and Gutterman, J. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene, 12: 1617-1623, 1996.
9. Link, C. J., Moorman, D., Seregina, T., Levy, J., and Schabold, K. A Phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum. Gene Ther., 7: 1161-1179, 1996.
10. Alvarez, R. D., and Curiel, D. T. A Phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-tk) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Hum. Gene Ther., 8: 597-613, 1997.
11. Sterman, D. H., Treat, J., Elshami, A. A., Amin, K., Molnar-Kimber, K., Coonrod, L., Recio, A., Wilson, J. M., Roberts, J. R., Litzky, L. A., Albelda, S. M., and Kaiser, L. R. Adenovirus mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a Phase I clinical trial in malignant mesothelioma. Hum. Gene Ther., 9: 1083-1092, 1998.
12. Chambers, R., Gillespie, G. Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J., Roizman, B., and Whitley, R. J. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA, 92: 1411-1415, 1995.
13. Jia, W. W-G., McDermott, M., Goldie, J., Cynader, M., Tan, J., and Tufaro, F. Selective destruction of gliomas in immunocompetent rats by thymidine kinase defective herpes simplex virus type 1. J. Natl. Cancer Inst., 86: 1209-1215, 1994.
14. Glorioso, J. C., DeLuca, N. A., and Fink, D. J. Development and application of herpes simplex virus vectors for human gene therapy. Annu. Rev. Microbiol., 49: 675-710, 1995.
15. Kesari, S., Randazzo, B., Valyi-Nagy, T., Huang, Q., Brown, S., MacLean, A., Lee, V., Trojanowski, J., and Fraser, N. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest., 73: 636-648, 1995.
16. Kramm, C. M., Chase, M., Herrlinger, U., Jacobs, A., Pechan, P. A., Rainov, N. G., Sena-Esteves, M., Aghi, M., Barnett, F. H., Chiocca, E. A., and Breakefield, X. O. Therapeutic efficiency and safety of a second-generation replication-conditional HSV 1 vector for brain tumor gene therapy. Hum. Gene Ther., 8: 2057-2068, 1997.
17. Nilaver, G., Muldoon, L. L., Kroll, R. A., Pagel, M. A., Breakefield, X. O., Davidson, B. L., and Neuwelt, E. A. Delivery of herpes virus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc. Natl. Acad. Sci. USA, 92: 9829-9833, 1995.
18. Martuza, R., Malick, A., Markert, J., Ruffner, K., and Coen, D. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (Washington DC), 252: 854-856, 1991.
19. Mineta, T., Rabkin, S., and Martuza, R. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res., 54: 3963-3966, 1994.
20. Mineta, T., Rabkin, S., Yazaki, T., Hunter, W., and Martuza, R. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1: 938-943, 1995.
21. Boviatsis, E., Chase, M., Wei, M., Tamiya, T., Hurford, R. J., Kowall, N., Tepper, R., Breakefield, X., and Chiocca, E. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum. Gene Ther., 5: 183-191, 1994.
22. Pyles, R. B., Warnick, R. E., Chalk, C., Szanti, B. E., and Parysek, L. A novel multiply mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther., 8: 533-544, 1997.
23. Randazzo, B., Kesari, S., Gesser, R., Alsop, D., Ford, J., Brown, S., MacLean, A., and Fraser, N. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology, 211: 94-101, 1995.
24. + between immediate early gene 1 and the 'a' sequence. J. Gen. Virol., 72: 631-639, 1991.
25. Taha, M., SM, B., Clements, G., and Graham, D. The JH2604 deletion variant of herpes simplex virus type 2 (HG52) fails to produce necrotizing encephalitis following intracranial inoculation of mice. J. Gen. Virol., 71: 1597-1601, 1990.
26. + γ-34.5 deletion mutant 1716 is avirulent in SCID mice. J. Gen. Virol., 75: 2059-2063, 1994.
27. Poon, A. P., and Roizman, B. Differentiation of the shutoff of protein synthesis by virion host shutoff and mutant γ (1)34.5 genes of herpes simplex virus 1. Virology, 229: 98-105, 1997.
28. Randazzo, B. P., Kucharczuk, J. C., Litzky, L. A., Kaiser, L. R., Brown, S. M., MacLean, A., Albelda, S. M., and Fraser, N. W. Herpes simplex 1716 - an ICP 34.5 mutant - is severely replication-restricted in human skin xenografts in vivo. Virology, 223: 392-395, 1996.
29. Brown, S., MacLean, A., Aitken, J., and Harland, J. ICP34.5 influences herpes simplex virus type I maturation and egress from infected cells in vitro. J. Gen. Virol., 75: 3767-3686, 1994.
30. Andreansky, S., Soroceanu, L., Flotte, E., Chou, J., Markert, J., Gillespie, G., Roizman, B., and Whitley, R. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res., 57: 1502-1509, 1997.
31. Yazaki, T., Manz, H., Rabkin, S., and Martuza, R. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res., 55: 4752-4756, 1995.
32. Kucharczuk, J. C., Randazzo, B., Elshami, A. A., Sterman, D. H., Amin, K. A., Molnar-Kimber, K. L., Brown, M. S., Litzky, L. A., Fraser, N. W., Albelda, S. M., and Kaiser, L. R. Use of a replication-restricted, recombinant herpes virus to treat localized human malignancy. Cancer Res., 57: 466-471, 1997.
33. Carroll, N., Chiocca, E., Takahashi, K., and Tanabe, K. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann. Surg., 224: 323-329, 1996.
34. Randazzo, B., Bhat, M., Kesari, S., Fraser, N., and Brown, S. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J. Invest. Dermatol., 108: 933-937, 1997.
35. Toda, M., Rabkin, S. D., and Martuza, R. L. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther., 9: 2173-2185, 1998.
36. Tainsky, M. A., Krizman, D. B., Chiao, P. J., Yim, S. O., and Giovanella, B. C. PA-1, a human cell model for multistage carcinogenesis: oncogenes and other factors. Anticancer Res., 8: 899-913, 1988.
37. Brandt, C., Imesch, P., Robinson, N., Syed, N., Untawale, S., Darjatmoko, S., Chappell, R., Heinzelman, P., and Albert, D. Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant. Virology, 229: 283-291, 1997.
38. Ito, M., Watanabe, M., Kamiya, H., and Sakurai, M. Herpes simplex virus type 1 induces apoptosis in peripheral blood T lymphocytes. J. Infect. Dis., 175: 1220-1224, 1997.
39. Wilson, S., Pedroza, L., Beuerman, R., and Hill, J. M. Herpes simplex virus type-1 infection of corneal epithelial cells induces apoptosis of the underlying keratocytes. Exp. Eye Res., 64: 775-779, 1997.
40. Brown, S. M., Harland, J., MacLean, A. R., Podlech, J., and Clements, J. B. Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. J. Gen. Virol, 75: 2367-2377, 1994.
41. McLaughlin, J. P., Abrams, S., Kantor, J., Dobrzanski, M. J., Greenbaum, J., Schlom, J., and Greiner, J. W. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity. J. Immunother., 20: 449-459, 1997.
42. Simons, J., Jaffee, E., Weber, C., Levitsky, H., Nelson, W., Carducci, M., Lazenby, A., Cohen, L., Finn, C., Clift, S., Hauda, K., Beck, L., Leiferman, K., Owens, A. J., Piantadosi, S., Dranoff, G., Mulligan, R., Pardoll, D., and Marshall, F. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res., 57: 1537-1546, 1997.
43. Ram, Z., Walbridge, S., EM, O., Vila, J., Yawen, C., Mueller, S., Blaese, M., and Oldfield, E. Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res., 54: 2141-2145, 1994.
44. Abdel-Wahab, Z., Weltz, C., Hester, D., Pickett, N., Vervaert, C., Barber, J. R., Jolly, D., and Seigler, H. F. A Phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer (Phila.), 80: 401-412, 1997.
45. Freeman, S. M., McCune, C., Robinson, W., Abboud, C. N., Abraham, G. N., Angel, C., and Marrogi, A. The treatment of ovarian cancer with a gene modified cancer vaccine: a Phase I study. Hum. Gene Ther., 6: 927-939, 1995.
46. Dingwell, K. S., Brunetti, C. R., Hendricks, R. L., Tang, Q., Tang, M., Rainbow, A. J., and Johnson, D. C. Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells. J. Virol., 68: 834-845, 1994.
47. Weeks, B. S., Sundaresan, P., Nagashunmugam, T., Kang, E., and Friedman, H. M. The herpes simplex virus-1 glycoprotein E (gE) mediates IgG binding and cell-to-cell spread through distinct gE domains. Biochem. Biophys. Res. Commun., 235: 31-35, 1997.
48. Gange, R. W., de Bats, A., Park, J. R., Bradstreet, C. M., and Rhodes, E. L. Cellular immunity and circulating antibody to herpes simplex virus in subjects with recurrent herpes simplex lesions and controls as measured by the mixed leukocyte migration inhibition test and complement fixation. Br. J. Dermatol., 93: 539-544, 1975.
49. Whitley, R. Herpes simplex viruses. In: B. N. Fields, D. M. Knipe, and P. M. Holey (eds.), Virology, Vol. 2, pp. 2297-2342. Philadelphia, PA: Lippincott-Raven Publishers, 1996.
50. Advani, S., Sibley, G., Song, P., Hallahan, D., Kataoka, Y., Roizman, B., and Weichselbaum, R. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther., 5: 160-165, 1998.
51. Brown, S. M., Ritchie, D. A., and Subak-Sharpe, J. H. Genetic studies with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map. J. Gen. Virol., 18: 329-346, 1973.
52. Ejercito, P. M., Kieff, E. D., and Roizman, B. Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J. Gen. Virol., 2: 357-364, 1968.
53. Dubin, G., Basu, S., Mallory, D., Basu, M., Tal-Singer, R., and Friedman, H. Characterization of domains of herpes simplex virus type 1 glycoprotein E involved in Fc binding activity for immunoglobulin G aggregates. J. Virol., 68: 2478-2485, 1994.
54. Eisenberg, R., Ponce de Leon, M., Friedman, H., Fries, L., Frank, M., Hastings, J., and Cohen, G. Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb. Pathog., 3: 423-435, 1987.
55. Wiertz, E., Mukherjee, S., and Ploegh, H. Viruses use stealth technology to escape from the host immune system. Mol. Med. Today, 3: 116-123, 1997.
56. Toda, M., Martuza, R., Kojima, H., and Rabkin, S. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol., 160: 4457-4464, 1998.
57. Andreansky, S., He, B., van Cott, J., McGhee, J., Markert, J. M., Gillespie, G. Y., Roizman, B., and Whitley, R. J. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther., 5: 121-130, 1998.
58. Fahy, G. T., Hooper, D. C., and Easty, D. L. Antigen presentation of herpes simplex virus by corneal epithelium-an in vitro and in vivo study. Br. J. Ophthalmol., 77: 440-444, 1993.
59. Chase, M., Chung, R. Y., and Chiocca, E. A. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol., 16: 444-448, 1998.
60. Oligino, T., Poliani, P. L., Wang, Y., Tsai, S. Y., O'Malley, B. W., Fink, D. J., and Glorioso, J. C. Drug-inducible transgene expression in brain using a herpes simplex virus vector. Gene Ther., 5: 491-496, 1998.